Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jan 16;4:3. doi: 10.1038/s41421-017-0002-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — a Ki67⁺ (red) and NG2⁺ pericyte (green) in T241-vector and T241–FGF-2 tumor tissue. Cell nuclei were counterstained with DAPI (blue). Allows point to Ki67⁺-NG2⁺ double positive pericytes. Bar = 50 μm. Images are obtained using immunohistochemistry. Quantification of percentages of Ki67⁺-NG2⁺ double positive pericytes tumors (n = 15 random fields; n = 4 mice for each group). b Ki67⁺ (red) and NG2⁺ pericyte (green) in vehicle (VT)-, BGJ398-, and imatinib-treated FGF-2⁺ tumor tissue. Allows point to Ki67⁺-NG2⁺ double positive pericytes. Withdrawal experimental settings were performed at day 6 after drug cessation. Images are acquired using immunohistochemistry. Bar = 50 μm. c Quantification of percentages of Ki67 ⁺-NG2⁺ double positive pericytes in VT-, BGJ398-, or imatinib-treated FGF-2⁺ tumors (n = 15 random fields; n = 4 mice for each group). d Pericyte in vitro proliferation after FGF-2 stimulation (n = 6 samples/group). e Pericyte in vitro migration after FGF-2 stimulation (n = 6 samples/group) P = 0.43. f Pericyte in vitro proliferation after PDGF-BB stimulation with or without FGF-2 pretreatment (n = 6 samples/group). g Pericyte in vitro migration after PDGF-BB stimulation with or without FGF-2 pretreatment (n = 6 samples/group). h FGF-2-induced proliferation of scrambled-siRNA-, Fgfr1-siRNA-, or Fgfr2-siRNA-transfected pericytes in vitro (n = 6 samples/group). i PDGF-BB-induced proliferation of scrambled-siRNA-, Fgfr1-siRNA-, or Fgfr2-siRNA-transfected pericytes with or without FGF-2 pretreatment in vitro (n = 6 samples/group). j PDGF-BB-induced migration of scrambled-siRNA-, Fgfr1-siRNA-, or Fgfr2-siRNA-transfected pericytes with or without FGF-2 pretreatment in vitro (n = 6 samples/group). All data as means ± S.E.M.; Student’s t test, *P < 0.05, **P < 0.01 and ***P < 0.001. All in vitro experiments were repeated at least twice